ライフサイエンスコーパス: DAPT

1 DAPT (aspirin and clopidogrel) for 24 versus 6 months.

2 DAPT continuation beyond 1 year showed no effects on mor

3 DAPT duration was categorised in each study as shorter v

4 DAPT duration was on the basis of patient characteristic

5 DAPT exposure resulted in a dramatic increase in neuroge

6 DAPT is indicated to lower the risk of ischemic events,

7 DAPT scores >/=2 were associated with reductions in MI/s

8 DAPT treatment causes a massive, coordinated differentia

9 months (n = 682) versus 12 months (n = 717) DAPT.

10 884 patients (44.9%) had a DAPT score of at least 2, and 1086 (55.1%) had a score l

11 and discharged on DAPT, cardiac events after DAPT cessation depend on the clinical circumstance and r

12 Only 2 ST events occurred after DAPT discontinuation between 30 and 90 days (both betwee

13 Notch cleavage via the pharmacological agent DAPT results in increased expression of neural marker ge

14 Among DAPT Study patients (derivation cohort; mean age, 61.3 y

15 p = 0.74) were observed between aspirin- and DAPT-treated patients, respectively.

16 ss and safety of concomitant use of PPIs and DAPT in the postdischarge treatment of unstable angina/n

17 By propensity and DAPT usage-adjusted multivariable analysis, permanent DA

18 Over 2 years, the overall incidence of any DAPT cessation was 57.3%.

19 poses a significant clinical dilemma because DAPT interruption exposes patients to the potential risk

20 the 5-year primary composite outcome between DAPT- and aspirin-treated patients (12.6% vs. 16.0%; adj

21 e sought to examine the relationship between DAPT discontinuation and stent thrombosis (ST) after cob

22 Attenuation of Notch signaling activity by DAPT or by morpholino knockdown of Notch1a is sufficient

23 ssed across randomized treatment arms and by DAPT score values <2 or >/=2.

24 nd human primary DCIS was reduced further by DAPT/lapatinib or DAPT/gefitinib regardless of ErbB2 rec

25 rmore, P493-6 tumorigenesis was inhibited by DAPT in vivo.

26 Notch inhibition by DAPT was also found to accelerate corneal epithelial wou

27 ble to CAC following inhibition of Notch1 by DAPT, shown by increased numbers of tumors and level of

28 ling in mind bomb (mib) mutant embryos or by DAPT treatment leads to increased numbers of lactotropes

29 mbryos, and inhibition of Notch signaling by DAPT partially rescued the apoptosis in zebrafish centra

30 Combined DAPT/lapatinib treatment was more effective at reducing

31 n (PCI) bleeding that occurs on contemporary DAPT and its impact on quality of life (QOL).

32 Conversely, continuing DAPT may be associated with excess bleeding complication

33 ents randomized to prolonged or short-course DAPT after implantation of newer-generation DES and in s

34 However, after damage, DAPT caused excessive regeneration of HCs at the expense

35 Following HC damage, DAPT had no direct effect on SC division.

36 omised controlled trials comparing different DAPT durations after drug-eluting stent implantation.

37 omized controlled trials evaluated different DAPT durations after percutaneous coronary intervention.

38 ssed within patients randomised to different DAPT durations (n=10 081) to identify the effect on blee

39 y and other clinical outcomes with different DAPT strategies.

40 quality evidence showed that longer-duration DAPT decreased risk for myocardial infarction (risk rati

41 major bleeding events than shorter-duration DAPT.

42 rediction of out-of-hospital bleeding during DAPT.

43 etyl-l-alanyl-S-phenylglycine t-butyl ester (DAPT) or dimethyl sulfoxide (control) during each DSS cy

44 yl]-l-alanyl)-S-phenylglycine t-butyl ester (DAPT) or following stable transfection with Notch1-short

45 )-L-alanyl]-(S)-phenylglycine t-butyl ester (DAPT) preferentially inhibited the neoplastic state in v

46 yl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT) significantly rescued Tat-impaired NPC differentia

47 yl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT), a chemical inhibitor of Notch receptor activation

48 yl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), a gamma-secretase inhibitor that blocks activatio

49 yl)-1-alanyl]-S-phenylglycine t-butyl ester (DAPT), or Notch1 short hairpin RNAs (shRNA) remarkably r

50 yl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), which significantly reduced adult survival and li

51 The authors have evaluated DAPT utilization rates and associated outcomes among pos

52 Extended DAPT is associated with approximately 8 fewer myocardial

53 Extended DAPT was associated with a reduction in the risk of myoc

54 In this meta-analysis, extended DAPT beyond 1 year prevented myocardial infarctions and

55 Compared with 1-year DAPT, extended DAPT did not affect all-cause mortality (odds ratio [OR]

56 tervals, 0.89-3.09) associated with extended DAPT.

57 e first 12 months, the benefits of extending DAPT were similar in subjects with and without complex l

58 Prespecified categories for DAPT cessation included physician-recommended discontinu

59 Incidence rates for DAPT cessation and adverse events were calculated as Kap

60 r time, depends on the underlying reason for DAPT cessation, or both is unknown.

61 paclitaxel-eluting stent patient subset from DAPT through reductions in MI and stent thrombosis.

62 A high DAPT score identified those experiencing the most benefi

63 Although higher DAPT scores identify patients with greater absolute isch

64 h could be reversed with the Notch inhibitor DAPT.

65 NOTCH1 inhibitor DAPT (GSI-IX) significantly reduces CSCs population and

66 aling, because the gamma-secretase inhibitor DAPT blocked its upregulation.

67 s inhibited by the gamma-secretase inhibitor DAPT or by inhibiting the function of Dll4, Jagged1, Not

68 signaling with the gamma-secretase inhibitor DAPT revealed that Notch and mecom did not have additive

69 Using gamma-secretase inhibitor DAPT to acutely block canonical Notch signaling, we iden

70 lizes BMP4 and the gamma-secretase inhibitor DAPT to induce SE differentiation from human induced plu

71 agged1 peptide and gamma secretase inhibitor DAPT, respectively.

72 tor GM6001 and the gamma-secretase inhibitor DAPT.

73 iation such as the gamma-secretase inhibitor DAPT.

74 sence or combination of the Notch inhibitor, DAPT, and ErbB1/2 inhibitors, lapatinib or gefitinib.

75 nt of chondrocytes with the Notch inhibitor, DAPT, decreased both endogenous and BMP2-induced SMAD 1/

76 pathways using a gamma-secretase inhibitor, DAPT (N-[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenylgl

77 f explants with a gamma-secretase inhibitor, DAPT, decreased Fgf20 mRNA, suggesting that Notch is ups

78 1 inhibition by a gamma-secretase inhibitor, DAPT, enhanced cell death in response to stress.

79 blocked using the gamma-secretase inhibitor, DAPT, or signaling was activated by misexpression of the

80 reatment with the gamma-secretase inhibitor, DAPT, to inhibit cleavage and release of Notch Intracell

81 re of cells to the gamma-secretase inhibitor-DAPT or silencing of Notch1 resulted in abrogation of co

82 h signaling using gamma secretase inhibitors DAPT and L-685,458 or anti-Jag1 antibody markedly decrea

83 e RPE, cells were pretreated with inhibitors DAPT or LY411575.

84 milar to that in patients never interrupting DAPT through 2 years (25/4067 [0.63%] versus 58/7152 [0.

85 The 2-year ST rate in patients interrupting DAPT at any time was similar to that in patients never i

86 comes for 2191 TL-PAS patients enrolled into DAPT were assessed.

87 ure, and longer dual antiplatelet therapy (L-DAPT) was defined as the per-protocol period of more pro

88 ause mortality was numerically higher with L-DAPT without reaching statistical significance.

89 Compared with L-DAPT, S-DAPT had an overall higher rate of stent thrombo

90 er rates of stent thrombosis compared with L-DAPT; the latter effect was significantly attenuated wit

91 ents treated for ISR may benefit from a long DAPT regimen.

92 oint (19 in short DAPT regimen vs. 8 in long DAPT regimen; p = 0.02).

93 regimen group compared with 7.3% in the long DAPT regimen group (p = 0.034).

94 lower occurrence of death and MI in the long DAPT regimen group as compared to the short DAPT regimen

95 whereas 110 patients were allocated to long DAPT regimen.

96 A longer DAPT duration significantly increased bleeding in patien

97 wer all-cause mortality compared with longer DAPT (HR 0.82, 95% CI 0.69-0.98; p=0.02; number needed t

98 mortality with shorter compared with longer DAPT was attributable to lower non-cardiac mortality (0.

99 d DAPT resulted in harm in patients with low DAPT scores undergoing PCI but reduced risk for ischemic

100 mmendations, various strategies for managing DAPT during the perioperative period have been proposed.

101 Median DAPT duration was 32 days (interquartile range [IQR]: 30

102 ly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin r

103 leaving 941 patients randomized to 24-month DAPT and 953 to 6-month DAPT.

104 for 6 months may be noninferior to 24-month DAPT in aspirin-sensitive patients.

105 rity was demonstrated for 6- versus 24-month DAPT, with an absolute risk difference of 0.11% (95% con

106 istance to aspirin to receive 6- or 24-month DAPT.

107 ary efficacy outcome with 24- versus 6-month DAPT was greater in patients with high scores (risk diff

108 imary safety outcome with 24- versus 6-month DAPT was greater in patients with low scores (RD for sco

109 ndomized to 24-month DAPT and 953 to 6-month DAPT.

110 noninferiority hypothesis of 6 vs. 12 months DAPT following second-generation DES implantation appear

111 to short (6 months) versus long (24 months) DAPT regimen.

112 c expression of NICD1 reversed the action of DAPT on drug sensitivity.

113 Retrospective assessment of DAPT score-guided treatment duration in a randomized cli

114 The rate of continuation of DAPT beyond 12 months was very low (5.4%).

115 f follow-up and stringent discontinuation of DAPT beyond 12 months, Resolute ZES and Xience V EES sho

116 s after BMS, and the appropriate duration of DAPT after BMS is unknown.

117 ined as the per-protocol minimum duration of DAPT after the procedure, and longer dual antiplatelet t

118 stratification to a prespecified duration of DAPT of 1, 6, or 12 months (group 2); or the reference a

119 estions: Q1) What is the minimum duration of DAPT required after DES implantation?

120 alanced, decisions regarding the duration of DAPT therapy must take into account patients' values and

121 re also similar by SYNTAX score, duration of DAPT therapy, completeness of revascularization, and in

122 ecisions surrounding the optimal duration of DAPT.

123 ed trials that tested different durations of DAPT after DES implantation: shorter dual antiplatelet t

124 arying covariates, we examined the effect of DAPT cessation on major adverse events (MACE [composite

125 Q3) What is the clinical effect of DAPT in stable patients who are >1 year past an MI?

126 To evaluate the safety and efficacy of DAPT duration according to DAPT score.

127 All adverse events and episodes of DAPT cessation were independently adjudicated.

128 scent vessels, and subcutaneous injection of DAPT in healthy skin reduced IL-33 expression, indicatin

129 Intratumoral injection of DAPT with cisplatin treatment significantly reduced CD13

130 ssed associations between different modes of DAPT cessation and cardiovascular risk after PCI.

131 Current guidelines suggest 12 months of DAPT after an initial presentation with ACS.

132 the noninferiority of 6 versus 12 months of DAPT in patients undergoing percutaneous coronary interv

133 ts taking aspirin who completed 12 months of DAPT without bleeding or ischemic events after receiving

134 12 months increases MI hazard regardless of DAPT score group.

135 imilarly, questions remain about the role of DAPT in long-term therapy of stable post-myocardial infa

136 y was to evaluate the efficacy and safety of DAPT after DES implantation.

137 CT of 15 603 patients to answer: A3): Use of DAPT >1 year after MI reduced the composite risk of card

138 y newer-generation DES to answer: A1) Use of DAPT for 12 months, as compared with use for 3 to 6 mont

139 A2) Use of DAPT for 18 to 48 months, compared with use for 6 to 12

140 The use of DAPT in patients with diabetes post-CABG in our cohort w

141 d-generation stents, and off-protocol use of DAPT in some studies.

142 ing outcomes, suggesting that routine use of DAPT may not be clinically warranted.

143 ar after AMI, associated with ongoing use of DAPT, and independently associated with worse QOL.

144 ore native coronary artery and discharged on DAPT were eligible for enrolment.

145 or patients undergoing PCI and discharged on DAPT, cardiac events after DAPT cessation depend on the

146 e most events after PCI occur in patients on DAPT, early risk for events due to disruption is substan

147 By contrast with patients who remained on DAPT, those who discontinued had lower MACE risk (0.63 [

148 Compared with those on DAPT, the adjusted hazard ratio (HR) for MACE due to int

149 aseline bleeding and mortality risk, ongoing DAPT was the strongest predictor of nuisance bleeding (r

150 CIS was reduced further by DAPT/lapatinib or DAPT/gefitinib regardless of ErbB2 receptor status.

151 DAPT (a gamma-secretase inhibitor) or PEDF + DAPT at the time of laser injury, or AAV2 infection 3 we

152 her received intravitreal injection of PEDF, DAPT (a gamma-secretase inhibitor) or PEDF + DAPT at the

153 e-adjusted multivariable analysis, permanent DAPT discontinuation before 30 days was independently as

154 days), and the association between permanent DAPT discontinuation and ST during this period is unclea

155 In this large pooled experience, permanent DAPT discontinuation before 30 days after cobalt chromiu

156 6.8 [8.4-85.4]; P<0.0001), whereas permanent DAPT discontinuation in any interval after 90 days was n

157 ard therapy with a vitamin K antagonist plus DAPT for 1, 6, or 12 months.

158 erapy or 2.5 mg rivaroxaban twice daily plus DAPT was associated with a reduced risk of all-cause mor

159 w-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months (group 2), or standard thera

160 usted vitamin K antagonist (once daily) plus DAPT for 1, 6, or 12 months (group 3).

161 12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleeding and thereby have a favorable

162 12 months or very-low-dose rivaroxaban plus DAPT for 1, 6, or 12 months was associated with a lower

163 ents compared with standard-of-care VKA plus DAPT.

164 The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, whit

165 INTERPRETATION: The PRECISE-DAPT score is a simple five-item risk score, which provi

166 Prolonged DAPT lowers the risk of ischemic events with no apparent

167 Prolonged DAPT resulted in harm in patients with low DAPT scores u

168 Improved selection of patients for prolonged DAPT may help minimize the incidence and adverse consequ

169 e <2) or benefit (score >/=2) from prolonged DAPT after percutaneous coronary intervention (PCI).

170 as the per-protocol period of more prolonged DAPT.

171 patients with PAD (5.2%) receiving prolonged DAPT relative to 8 (6.9%) of those receiving short DAPT

172 es moderately strong evidence that prolonged DAPT after implantation of newer-generation DES entails

173 cacy outcome varied by stent type; prolonged DAPT with high scores was effective only in patients rec

174 Whether prolonged DAPT benefits patients with high scores treated with con

175 idence of increased mortality with prolonged DAPT after DES implantation.

176 9) per 1000 patients treated with prolonged DAPT per year.

177 idence of increased mortality with prolonged DAPT.

178 Prolonging DAPT requires careful assessment of the trade-off betwee

179 ) What is the clinical benefit of prolonging DAPT up to 18 to 48 months?

180 gest that in selected populations prolonging DAPT does not offer additional protection from ischemic

181 Among 11,648 randomized DAPT Study patients from 11 countries (August 2009-May 2

182 ays post-CABG, 544 (68.4%) patients received DAPT and 251 (31.6%) patients received aspirin alone.

183 sease) trial, we compared patients receiving DAPT (aspirin plus thienopyridine) and aspirin monothera

184 fficacy of PPI therapy in patients receiving DAPT in low- and high-dose aspirin subsets.

185 outcomes were similar for patients receiving DAPT versus aspirin monotherapy respectively, in subgrou

186 atients, the majority of whom were receiving DAPT, was approximately 1.4% at 3 years.

187 s undergo noncardiac surgery and may require DAPT interruption.

188 ients with coronary artery disease requiring DAPT, even if the patients are on low-dose aspirin.

189 S-DAPT had an overall significantly lower risk of CSB (OR:

190 S-DAPT had overall lower rates of bleeding yet higher rate

191 Compared with L-DAPT, S-DAPT had an overall higher rate of stent thrombosis (odd

192 The effect of S-DAPT on stent thrombosis was attenuated with the use of

193 tation: shorter dual antiplatelet therapy (S-DAPT) was defined as the per-protocol minimum duration o

194 all-cause mortality rate was observed with S-DAPT (OR: 0.87 [95% CI: 0.74 to 1.01]; p = 0.073).

195 tment with the inhibitor of gamma-secretase (DAPT) led to the blockage of the expressions of reprogra

196 leeding complications between long and short DAPT regimen.

197 ts reached the primary endpoint (19 in short DAPT regimen vs. 8 in long DAPT regimen; p = 0.02).

198 elative to 8 (6.9%) of those receiving short DAPT (HR, 0.77; 95% CI, 0.27-2.21; P = .62), with a sign

199 ged group and 66.8 (11.3) years in the short DAPT group, and 667 (76.8%) were male in the prolonged g

200 nged group and 75.7 (8.7) years in the short DAPT group, and 97 (82.2%) were male in the prolonged gr

201 group and 92 (71.9%) were male in the short DAPT group.

202 group and 655 (76.6%) were male in the short DAPT group.

203 DAPT regimen group as compared to the short DAPT regimen group (6.5% vs. 15.5%; p = 0.03).

204 endpoint at 24 months was 16.7% in the short DAPT regimen group compared with 7.3% in the long DAPT r

205 verall, 114 patients were allocated to short DAPT regimen, whereas 110 patients were allocated to lon

206 Prolonged vs short DAPT conveyed a lower risk of the primary efficacy end p

207 D treated with prolonged compared with short DAPT (HR, 0.07; 95% CI, 0-1.21; P = .01).

208 Shorter DAPT was also associated with a lower risk of major blee

209 frequentist pairwise meta-analysis, shorter DAPT was associated with significantly lower all-cause m

210 is, patients treated with 6-month or shorter DAPT and 1-year DAPT had higher risk of myocardial infar

211 rm of dose-adjusted VKA daily with a similar DAPT stratification (group 3).

212 grel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus

213 (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT00977938).

214 tics, combined with an abbreviated, tailored DAPT regimen, resulted in a lower risk of 1-year MACE in

215 ch (74%) occurred while patients were taking DAPT.

216 In this study we demonstrate that DAPT reduced acini size and mammosphere formation in MCF

217 from a large-scale registry illustrate that DAPT durations beyond 6 months are associated with lower

218 High-quality evidence showed that DAPT increased risk for major bleeding (RR, 1.63 [CI, 1.

219 The DAPT (Dual Antiplatelet Therapy) study enrolled patients

220 The DAPT (Dual Antiplatelet Therapy) Study, a double-blind t

221 The DAPT coprimary composite end point (death, myocardial in

222 The DAPT coprimary end point, stent thrombosis, was also low

223 The DAPT effect was also evaluated in vivo in a mouse model

224 The DAPT score improves prediction of patient benefit and ha

225 In the DAPT Study (Dual Antiplatelet Therapy), after percutaneo

226 In the DAPT Study, combined myocardial infarction (MI) or stent

227 Including the DAPT Study, we identified 14 eligible trials that random

228 iscontinuation of dual antiplatelet therapy (DAPT) after 12 months.

229 timum duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent placement remain

230 timal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is unc

231 riate duration of dual-antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement remains c

232 timal duration of dual antiplatelet therapy (DAPT) after implantation of newer-generation drug-elutin

233 rsus 12 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) bas

234 tents, and use of dual antiplatelet therapy (DAPT) at randomization.

235 Although dual antiplatelet therapy (DAPT) beyond 1 year provides ischemic event protection a

236 Dual antiplatelet therapy (DAPT) cessation increases the risk of adverse events aft

237 fits and harms of dual antiplatelet therapy (DAPT) continuation beyond 1 year after drug-eluting sten

238 timal duration of dual antiplatelet therapy (DAPT) following second-generation drug-eluting stent (DE

239 bitors (PPIs) and dual antiplatelet therapy (DAPT) for cardiovascular outcomes.

240 Dual antiplatelet therapy (DAPT) has been the mainstay of efforts to prevent stent

241 ended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 month

242 nd post-operative dual antiplatelet therapy (DAPT) in patients who undergo coronary artery bypass gra

243 timal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS).

244 ort (</=6 months) dual antiplatelet therapy (DAPT) in patients with PAD undergoing PCI.

245 Whether premature dual antiplatelet therapy (DAPT) interruption is safe in patients receiving cobalt

246 Dual antiplatelet therapy (DAPT) is prescribed to millions of patients worldwide fo

247 Prolonged dual antiplatelet therapy (DAPT) is recommended after acute myocardial infarction (

248 Prolonged dual antiplatelet therapy (DAPT) is recommended after an acute myocardial infarctio

249 Outcomes with dual antiplatelet therapy (DAPT) or triple therapy (DAPT plus warfarin) were compar

250 long (24 months) dual antiplatelet therapy (DAPT) regimen.

251 The dual-antiplatelet therapy (DAPT) score was developed to identify patients more like

252 ticipating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified analysis.

253 rom data from the Dual Antiplatelet Therapy (DAPT) Study, a multicenter trial involving 220 US and in

254 In the Dual Antiplatelet Therapy (DAPT) Study, continuation of dual antiplatelet therapy b

255 K antagonist plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and aspirin reduces the ris

256 Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischa

257 Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard a

258 of bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a stable

259 gonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleedin

260 ilar durations of dual-antiplatelet therapy (DAPT).

261 atients requiring dual antiplatelet therapy (DAPT).

262 tiplatelet therapy (DAPT) or triple therapy (DAPT plus warfarin) were compared using Cox proportional

263 inite/probable ST were analyzed according to DAPT discontinuation in the following time intervals: 0

264 ty characteristics and compared according to DAPT score.

265 y and efficacy of DAPT duration according to DAPT score.

266 te/severe) events were compared according to DAPT score.

267 mortality and ischaemic events when added to DAPT, but caused increased bleeding.

268 essed the effect of omeprazole when added to DAPT; the other 30 (observational) assessed the effect o

269 ing in vivo was validated in mice exposed to DAPT, which failed to demonstrate barrier disruption fol

270 Relative to DAPT, patients on triple therapy had a similar risk of M

271 sought to determine whether a decision tool (DAPT score) aids prescription of dual antiplatelet thera

272 try demonstrated that the context underlying DAPT cessation is an additional correlate of outcomes af

273 Notch inhibition using DAPT and using Notch1-shRNA both enhanced in vitro migra

274 nalysis may have been limited by the varying DAPT durations among studies.

275 Those receiving triple therapy versus DAPT had higher rates of major bleeding without a measur

276 ark analyses comparing triple therapy versus DAPT in patients persistently on warfarin versus those n

277 eded to treat=10), and 41.9% in group 3 (VKA+DAPT).

278 ion was strongly associated with ST, whereas DAPT discontinuation beyond 90 days appeared safe.

279 s of post-discharge "nuisance" bleeding with DAPT and its impact on quality of life (QOL) are unknown

280 e frequency and time course of bleeding with DAPT in patients with established vascular disease or ri

281 iovascular outcomes when coadministered with DAPT.

282 Among patients with DAPT scores <2 in both groups, continued thienopyridine

283 During months 12 to 15, patients with DAPT scores <2 or >/=2 both had lower rates of MI with c

284 ubjects with anatomic complexity, those with DAPT scores >/=2 randomized to continued thienopyridine

285 A total of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspir

286 elevation myocardial infarction treated with DAPT are warranted.

287 Patients treated with DAPT for 6 months or shorter had similar rates of mortal

288 ortality compared with patients treated with DAPT for longer than 1 year.

289 Among stented patients with ACS treated with DAPT, the administration of twice-daily rivaroxaban 2.5

290 d during the period of active treatment with DAPT (HR: 0.68; 95% CI: 0.50 to 0.92, combined rivaroxab

291 Although treatment with DAPT beyond 1 year after drug-eluting stent implantation

292 ypothesized that antiplatelet treatment with DAPT for 6 months may be noninferior to 24-month DAPT in

293 Treatment with DAPT, a gamma-secretase inhibitor, similarly interfered

294 In vitro treatment with DAPT, an inhibitor of Notch activity, had no effect on S

295 mpared longer than 1-year DAPT versus 1-year DAPT after drug-eluting stenting.

296 ated with 6-month or shorter DAPT and 1-year DAPT had higher risk of myocardial infarction and stent

297 g stent implantation as compared with 1-year DAPT remain controversial.

298 ized trials that compared longer than 1-year DAPT versus 1-year DAPT after drug-eluting stenting.

299 Compared with 1-year DAPT, extended DAPT did not affect all-cause mortality (

300 eeding than did patients treated with 1-year DAPT.